Search results for "endothelial NO synthase"

showing 2 items of 2 documents

Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia

2018

javax.xml.bind.JAXBElement@6f8948ff Hypoxia represents both an outcome of cardiopulmonary diseases and a trigger for severe pulmonary complications as pulmonary hypertension. Because nitric oxide (NO) is a critical mediator in the development of pulmonary hypertension, the modulators of its downstream function may become target of pharmacological interventions aimed at alleviating the impact of this condition. Here, we investigate the effects of an early administration of phosphodiesterase-5 inhibitor in rats where pulmonary artery hypertension was induced by chronic exposure to hypoxia. javax.xml.bind.JAXBElement@162dc677 Rats were divided into three groups: normoxic control, hypoxic with …

0301 basic medicinemedicine.medical_specialtynitrites and nitratesPhysiologySildenafilsildenafil030204 cardiovascular system & hematologyphosphodiesterase 5lcsh:PhysiologyNitric oxideendothelial NO synthase; nitric oxide; nitrites and nitrates; phosphodiesterase 5; pulmonary hypertension; pulmonary vascular remodeling; right heart failure; sildenafil03 medical and health scienceschemistry.chemical_compound0302 clinical medicinenitric oxidePhysiology (medical)medicine.arteryInternal medicinepulmonary hypertensionmedicineendothelial NO synthaseOriginal ResearchCardiopulmonary diseaseLunglcsh:QP1-981business.industryright heart failureHypoxia (medical)medicine.diseasePulmonary hypertension030104 developmental biologymedicine.anatomical_structurechemistryVentriclePulmonary arteryCardiologymedicine.symptombusinesspulmonary vascular remodelingFrontiers in Physiology
researchProduct

ERYTHROPOIETIN FOR THE TREATMENT OF SUBARACHNOID HEMORRAGE: A FEASIBLE INGREDIENT FOR A SUCCESS MEDICAL RECIPE

2015

Subarachnoid hemorrhage (SAH) following aneurysm bleeding accounts for 6% to 8% of all cerebrovascular accidents. Although an aneurysm can be effectively managed by surgery or endovascular therapy, delayed cerebral ischemia is diagnosed in a high percentage of patients resulting in significant morbidity and mortality. Cerebral vasospasm occurs in more than half of all patients after aneurysm rupture and is recognized as the leading cause of delayed cerebral ischemia after SAH. Hemodynamic strategies and endovascular procedures may be considered for the treatment of cerebral vasospasm. In recent years, the mechanisms contributing to the development of vasospasm, abnormal reactivity of cerebr…

Subarachnoid hemorrhagebusiness.industrySettore MED/27 - NeurochirurgiaCerebral arteriesIschemiaHemodynamicsVasospasmReview Articlemedicine.diseasenervous system diseasesCerebral vasospasmAneurysmErythropoietinAnesthesiaRECOMBINANT-HUMAN-ERYTHROPOIETIN NITRIC-OXIDE SYNTHASE ENDOTHELIAL NO SYNTHASE BLOOD-BRAIN-BARRIER IN-VIVO EVIDENCE CEREBRAL-ISCHEMIA DARBEPOETIN-ALPHA TISSUE PROTECTION DOUBLE-BLIND RECEPTORGeneticscardiovascular systemMolecular MedicineMedicinecardiovascular diseasesbusinessMolecular BiologyGenetics (clinical)medicine.drugsubarachnoid hemorrage erytropoietin
researchProduct